The association between UGT1A1 polymorphisms and treatment toxicities of liposomal irinotecan

BACKGROUND: Initial dose adjustment is recommended for patients with known UGT1A1∗28 homozygosity for both conventional irinotecan and liposomal irinotecan (nal-IRI). A recent population pharmacokinetic (PK) study showed that Asian patients had a lower prevalence of UGT1A1∗28 homozygosity but a sign...

Descripción completa

Detalles Bibliográficos
Autores principales: Su, Y.-Y., Chiang, N.-J., Chang, J.S., Wang, Y.-W., Shen, B.-N., Li, Y.-J., Hwang, D.-Y., Shan, Y.-S., Chen, L.-T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10024091/
https://www.ncbi.nlm.nih.gov/pubmed/36527823
http://dx.doi.org/10.1016/j.esmoop.2022.100746

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10024091/
https://www.ncbi.nlm.nih.gov/pubmed/36527823
http://dx.doi.org/10.1016/j.esmoop.2022.100746

Ejemplares similares